Rare diseases
Investigational molecules
Locations
Level 4 175 Scott Street, 2300
Clinical research in early stage triple negative breast cancer focuses on neoadjuvant immunotherapy and chemotherapy, with interest in treatment strategies for stage I-II disease and the role of immune checkpoint inhibition in primary breast tumours.
The sponsor’s work in this area is centred on breast cancer treatment innovation through immune-based approaches for aggressive early disease.
ANZ Breast Cancer Trials Group Limited runs clinical trials in conditions such as Breast cancer, Prophylaxis, BRCA1 gene mutation, Triple negative breast cancer, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
Austria
ItalyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
